Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (345)	5/27/2003 11:26:08 AM
From: phbolton	Read Replies (1) \| Respond to of 523

NRGN is having another active day, the past couple of weeks has had a few 250k trades, and hence a big uptick in volume, another spike in the price today, no obvious news....... anyone have any clues?????

To: scaram(o)uche who wrote (345)	6/12/2005 2:32:52 AM
From: tuck	Read Replies (2) \| Respond to of 523

IP for VR1 antagonists (follow-up of previous post): appft1.uspto.gov Abbott appft1.uspto.gov Merck (pre NRGN?) appft1.uspto.gov Novartis appft1.uspto.gov GSK appft1.uspto.gov J&J, with intersting snip: "Walpole and colleagues at Sandoz reported on the first competitive antagonist of the sensory neuron excitants capsaicin and resineriferatoxin (Walpole, C. S. J. et. al., J. Med. Chem. 1994, 37,1942). Subsequently, capsazepine has been shown to be a vanilloid receptor antagonist. Capsazepine, however, is not naphthol, quinoline and isoquinoline-derived. Jee Woo Lee and colleagues at Pacific Corporation disclosed thiocarbamic acid derived VR1 antagonists in WO0216317A1 and vanilloid receptor modulators in WO0216318A1 and WO0216319A1 but these applications do not disclose or describe N-naphthol, quinoline and isoquinoline-derived N'-benzylic ureas. Hutchinson and colleagues at Neurogen describe diaryl piperazinyl ureas and related compounds as capsaicin receptor ligands in WO02082212A1 but N-naphthol, quinoline and isoquinoline-derived N'-benzylic ureas are not covered. Scientists at the Universidad Miguel Hernandez in Alicante, the Universidad de Valencia and the Consejo Superior de Investigaciones Cientificas (CSIC) in Barcelona have used a combinatorial chemistry-based approach to discover compounds that modulate the vanilloid VR1 receptor and have disclosed two trialkylglycine-based compounds as noncompetitive VR1 channel blockers (Garcia-Martinez, C. et al. Proc Natl Acad Sci USA 2002, 99(4): 2374) but none are naphthol, quinoline and isoquinoline-derived." emphasis mine I couldn't seem to find this Hutchinson patent app at the EPO. Not sure what I'm doing wrong. Rick, I know you're good at this, help! Edit: spoke too soon; it just took 3 tries to find which keywords worked . . . sorry to bother you . . . v3.espacenet.com Hutchinson/Neurogen patent app. Cheers, Tuck